Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Piacenza – page 26

667 clinical trials in Piacenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Piacenza at a glance
667
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

667 trials in Piacenza

Open in trial search

Neoplasm

Not yet recruiting

Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Centro Nazionale Di Adroterapia Oncologica

Non-small cell lung cancer+1

Not yet recruiting

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Universita' Degli Studi Di Torino

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Pulmonary embolism+1

Not yet recruiting

Study on Sulodexide for Preventing Recurrence of Blood Clots in Elderly Patients After First Episode of Deep Vein Thrombosis or Pulmonary Embolism

Registered drug
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Sulodexide
  • Sponsor:Fondazione Arianna Anticoagulazione

Cervical dysplasia+1

Not yet recruiting

Study on Pembrolizumab for Patients with High-Grade HPV-Related Vulvar and Cervical Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Chronic kidney disease

Not yet recruiting

Study on Finerenone for Slowing Chronic Kidney Disease Progression in Patients Receiving Standard Care

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:The George Institute For Global Health

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darbepoetin Alfa
  • Sponsor:Genexine Inc.

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Asso De Recherche Cancers Gynecologiques

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Piacenza

What the registry says about research in the country

01 Hematological Malignancies

Innovative clinical trials focusing on chronic myeloid leukemia, lymphomas, and various blood cancers, evaluating targeted therapies and combination treatments.

  • BCR-ABL1+ CML Treatment
  • Follicular Lymphoma Studies
  • Acute Myeloid Leukemia Research

Research emphasizes personalized treatment approaches and maintenance strategies for better patient outcomes.

02 Solid Tumors

Studies investigating advanced treatments for lung cancer, breast cancer, and pancreatic cancer, with focus on targeted and immunotherapy approaches.

  • NSCLC Treatment Sequences
  • Breast Cancer Hormone Therapy
  • Pancreatic Adenocarcinoma Studies

Trials explore novel drug combinations and treatment sequencing strategies.

03 Gynecologic Oncology

Clinical research examining treatments for ovarian cancer and related conditions, testing innovative therapeutic approaches and maintenance strategies.

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer Studies

Focus on hormone receptor-positive cancers and targeted treatment combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.